Phase III data on bluebird bio's Zynteglo, as well as Vertex and CRISPR Therapeutics' CTX001, showed patients achieving transfusion independence via two gene therapy approaches.
The company presented updated data for the drug, voxelotor, at the European Hematology Association conference in Amsterdam Friday.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
On Saturday, the company will present a poster of Phase I trial data for belantamab mafodotin, which targets the same antigen, BCMA, as Amgen bispecific antibody AMG 420 and multiple CAR-T cell therapies in development.
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.